26 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
obligations under a financial instrument or customer contract, leading to a financial loss. We are exposed to credit risk primarily from our treasury … range of pricing, discounting, education, marketing and promotion, sales commission, customer incentive programs and other business arrangements
POS AM
NAMS
NewAmsterdam Pharma Company NV
12 Apr 24
Prospectus update (post-effective amendment)
4:15pm
of beneficial interests in a registered global security held through participants will be governed by standing customer instructions and customary practices
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained … .
Credit Risk
Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading
8-K
EX-1.1
NAMS
NewAmsterdam Pharma Company NV
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.
(v) Intellectual … number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as “personally identifying
424B5
NAMS
NewAmsterdam Pharma Company NV
15 Feb 24
Prospectus supplement for primary offering
4:15pm
(1) of Directive 2014/65/EU (as amended, “MiFID II”); or (ii) a customer within the meaning of Directive (EU) 2016/97 (as amended, the “Insurance … Distribution Directive”), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II
424B5
kf0zfx12
13 Feb 24
Prospectus supplement for primary offering
5:19pm
F-3
ez3lpniwedmmn1z636k
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
EX-1.2
79v6z6 d2a5wp
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
o90ghd8 seafihi1rzy
15 Aug 23
Prospectus supplement
4:52pm
POS AM
4a85m jlkpgtp7hak
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
y84kra1rbnwiwteou40g
7 Aug 23
Research and development expenses
7:24am
424B3
l723bbfym es
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-1.1
87h r07xtnggc0vn1e
9 Jun 23
Current report (foreign)
9:39pm
424B3
vmpu5i0q0 xcga
8 Jun 23
Prospectus supplement
5:01pm
424B3
fcjsy wbqor
6 Jun 23
Prospectus supplement
4:20pm
424B3
2ne syxqe0mdbw7
25 Apr 23
Prospectus supplement
8:14am
POS AM
7rfsv8676n8g
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
0v98m4b7ssqb01
19 Dec 22
Registration statement (foreign)
6:22pm
6-K
EX-2.1
tq08ivih 9vx
23 Nov 22
Current report (foreign)
4:36pm